Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ajay Varanasi

Endocrinology, Diabetes & Metabolism St Petersburg, FL Medical Doctor

NPI 1104982420 CMS profile 50608

5775 5Th Ave N, St Petersburg, FL 33710

Open in the dashboard

General payments

$159,547

443 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,370 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Ajay Varanasi of St Petersburg, FL is reported in the CMS Open Payments database as having received $159,547 across 443 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $5,370 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $54,469 92
2024 General $11,047 48
2023 General $17,910 72
2022 General $855 44
2021 General $2,710 25
2020 General $20,451 43
2019 General $52,105 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ajay Varanasi
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Ajay Varanasi were reported at $54,469. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Ajay Varanasi Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $52,105 $494 $123–$2,253 $163
2020 $20,451 $335 $85–$1,841 $114
2021 $2,710 $398 $88–$1,981 $132
2022 $855 $364 $88–$1,568 $149
2023 $17,910 $420 $113–$1,614 $160
2024 $11,047 $440 $121–$1,646 $164
2025 $54,469 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $51,325 112 payments
  2. Ascendis Pharma, Inc. $45,026 37 payments
  3. Dexcom, Inc. $35,744 65 payments
  4. Lilly USA, LLC $9,824 48 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $9,820 25 payments
  6. AstraZeneca Pharmaceuticals LP $4,591 19 payments
  7. Abbott Laboratories $817 16 payments
  8. Tandem Diabetes Care, Inc. $312 19 payments
  9. Medtronic MiniMed, Inc. $205 22 payments
  10. Insulet Corporation $195 7 payments
  11. Other $1,688 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $106,135 58 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $31,024 10 payments
  3. Travel and Lodging $9,839 23 payments
  4. Food and Beverage $9,594 347 payments
  5. Consulting Fee $2,925 1 payment
  6. Education $30 4 payments
Products named General payments · program years 2019–2025
  1. Yorvipath $39,059 32 payments
  2. DEXCOM G7 GSS (161) $35,254 27 payments
  3. Ozempic $22,701 81 payments
  4. Tresiba Diabetes $11,895 44 payments
  5. JARDIANCE Diabetes $9,770 23 payments
  6. JARDIANCE Diabetes $9,474 26 payments
  7. DEXCOM STELO GLUCOSE BIOSENSOR $8,281 5 payments
  8. Tresiba Diabetes $6,460 1 payment
  9. FARXIGA $4,567 18 payments
  10. RYBELSUS $3,273 55 payments
  11. Other $4,831 242 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 112 drugs

Part D claims

10,765

Median for Endocrinology: 1,959

Drug cost

$4,973,740

Median for Endocrinology: $890,201

Branded share of claims

50.2%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 729 $1,142,939
Mounjaro Tirzepatide Brand 434 $709,220
Trulicity Dulaglutide Brand 351 $573,343
Jardiance Empagliflozin Brand 362 $465,850
Tresiba Flextouch U-200 Insulin Degludec Brand 255 $280,073
Farxiga Dapagliflozin Propanediol Brand 167 $207,272
Januvia Sitagliptin Phosphate Brand 130 $156,350
Tresiba Flextouch U-100 Insulin Degludec Brand 196 $145,004
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 60 $106,514
Rybelsus Semaglutide Brand 31 $81,338

The 10 drugs with the highest cost, of 112 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$275,409

Medicare's payments for the services billed

Medicare patients

683

Average age 74

Services billed

3,642

433 women, 250 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 58%
Arthritis 47%
Chronic kidney disease 35%
Ischemic heart disease 32%
Depression 24%
Osteoporosis 22%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $81
  • Boehringer Ingelheim Pharmaceuticals, Inc. $23
$104 362 —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $48
$48 — —
ZEPBOUND
  • Lilly USA, LLC $34
$34 — —
MOUNJARO
  • Lilly USA, LLC $28
$28 434 —
Korlym
  • Corcept Therapeutics $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

443 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record